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ABSTRACT
In 2011, the International Osteoporosis Foundation and the International Federation of Clinical Chemistry and Laboratory Medicine
selected serum collagen type-I crosslinked C-peptide (s-CTX) as the reference standard for bone resorption. This study aimed to deter-
mine the within and between laboratory reproducibility for s-CTX assays. To create standardized pools, serum was collected from
10 premenopausal and 10 postmenopausal women. Premenopausal sera were pooled to approximate a population with normal
bone turnover; postmenopausal sera were pooled to approximate a population with high bone turnover; and a third pool was cre-
ated from an equal proportion of the pre- and postmenopausal pools. Multiple identical aliquots from each pool were created and
frozen; all were labeled as routine clinical specimens. To evaluate longitudinal laboratory reproducibility, an identical aliquot from
each of the three pools was sent to four US commercial laboratories on five dates over a 6-month period. To evaluate within-run
reproducibility, each lab received five identical aliquots from each pool on the fifth date. Three labs (Mayo, ARUP, and Quest) used
the Roche Diagnostics Elecsys assay, and one (Esoterix/LabCorp) used the IDS-iSYS assay. Reproducibility was assessed using the
coefficient of variation (CV) with 95% confidence intervals (CIs). Labs were unaware of the investigation. Across labs, mean s-CTX
values were 423, 533, and 480 pg/mL for the premenopausal, postmenopausal, and mixed pools, respectively, but the means dif-
fered between labs (p < 0.001). The premenopausal pool longitudinal CVs ranged from 5.0% to 14.9%; the postmenopausal pool
CVs ranged from 3.4% to 19.3%; and the mixed pool CVs ranged from 3.3% to 16.0%. The longitudinal reproducibility for Esoter-
ix/LabCorp was higher (CV 13.9%; 95% CI, 10.1% to 22.2%) than for the other labs. Within-run CVs were also higher for Esoterix/
LabCorp (CV 8.6%; 95% CI, 6.3% to 13.6%) compared with the other labs (CVs 2.1% to 6.2%). In conclusion, the reproducibility of
s-CTX varied across US commercial labs, and was poorer for Esoterix/LabCorp, which used the IDS assay, compared with the other
three labs, which used the Roche assay. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American
Society for Bone and Mineral Research.
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Introduction
The field of bone turnovermarkers (BTMs) has developed con-siderably over the past decade. A significant amount of
research has suggested that BTMs may provide useful informa-
tion on fracture risk and may also have the potential to predict
response to treatment for osteoporosis.(1) These findings have
secured a place for the use of BTMs in clinical research and
research trials of new therapies as secondary endpoints of treat-
ment efficacy. However, the use of BTMs in clinical practice has
been limited by a number of factors, including the heterogeneity
of assays and laboratory quality control. This variability pro-
foundly limits the application of research findings to individual-
ized patient care.(2–6)
To address some of the uncertainties regarding the clinical utility
of BTMs, the International Osteoporosis Foundation (IOF) and the
International Federation of Clinical Chemistry and Laboratory Med-
icine (IFCC) have recommended that reference markers, measured
by standardized assays, be adopted for use in clinical trials and
observational studies in osteoporosis to (1) enhance laboratory
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consistency, (2) broaden the international experience of the clinical
application of BTMs to osteoporosis, and (3) facilitate their inclusion
in routine clinical practice. In 2011, the IOF–IFCC selected
serum collagen type-I cross-linked C-peptide (s-CTX) as the
reference standard for bone resorption and serum amino-
terminal type-I procollagen (s-PINP) as the reference standard
for bone formation.(2)
An important next step beyond the identification of reference
BTMs is the standardization of the measurement of each marker
with the aim of obtaining comparable values over time for each
marker irrespective of the laboratory in which the measurement
is made or the method utilized.(2,7) Over the last decade, many of
the traditional BTM immunoassays have been automated,
improving technical performance and increasing their availabil-
ity. Nevertheless, analytical aspects, such as within- and
between-batch precision, accuracy, and standardization, remain
problematic.(8) Potential contributors to these variations include,
but are not limited to, the specific analytical methods (eg, auto-
mated versus nonautomated platform), sample collection (eg,
sample handling procedures), and laboratory performance (eg,
sample analysis, calibration).(5–8)
Previously, we reported substantial differences across US com-
mercial labs when assessing the reproducibility of urine NTx and
serum bone-specific alkaline phosphatase.(9) In the current study,
we aimed to extend our previous findings to determine the
within- and between-laboratory variability of measurements of
s-CTX performed by US commercial labs under routine clinical
conditions.
Materials and Methods
Participants
Pre- and postmenopausal women (postmenopausal women at
least 10 years from last menstrual period), who were generally
in good health, were recruited via advertising flyers posted
around a large academic medical center. Volunteers were
excluded if they were using pharmacotherapy for osteoporosis,
defined as the current use of estrogen, calcitonin, a selective
estrogen receptor modulator (SERM), bisphosphonates, denosu-
mab, or teriparatide. The use of calcium and/or vitamin D supple-
ments, as well as contraceptives, was permitted. Participants
were also excluded if they had self-reported major medical con-
ditions known to affect bone turnover, specifically Paget disease,
chronic kidney disease, end-stage renal disease, hyperthyroid-
ism, hyperparathyroidism, and active inflammatory disease. Indi-
viduals with a recent fracture were not identified or excluded
from enrollment. All volunteers provided written informed con-
sent after reading an information sheet that described the mini-
mal risks involved in participation. The Institutional Review Board
of the University of California, San Francisco (UCSF) approved the
study protocol prior to initiation of the study.
Creation of serum pools
Tominimize the interfering effects of medications or other factors
specific to a single volunteer, sera from individuals were pooled.
Three pools of sera were created from specimens obtained from
20 volunteers (10 premenopausalwomenand10postmenopausal
women) to approximate populations with normal and high levels
of bone turnover. A third pool was created by equally mixing sera
from pre- and postmenopausal women to approximate a popula-
tion with intermediate levels of bone turnover.
To create the pools of sera, fasting blood was collected before
10 a.m. in six red-top serum separator tubes fromeach participating
woman. The blood was then allowed to clot at room temperature
for 15 to 20 min, then was immediately placed on ice, centrifuged
for 15 min, and separated. The serum from each individual partici-
pant was stored at –80C in 10-mL tubes until all volunteer samples
were collected and ready for pooling. Once all volunteer samples
were collected, the sera from each participant was thawed and
pooled on the same day. Using a clean disposable pipette, sera
from the 10 premenopausal womenwere pooled into a sterile flask
and stirred for 10 min in an ice-water bath. This process was
repeated with sera from the 10 postmenopausal volunteers using
a separate pipette and flask. To create the mixed pool of sera, an
equal volume of serum from the premenopause pool and the post-
menopause pool was drawn and combined into a third flask, then
mixed 40 times with a glass stirrer. The resulting three pools of sera
(premenopause, postmenopause, and mixed) were then divided
into 0.5-mL aliquots and placed into cryovials, flash-frozen, and
stored at –80C. Each cryovial was labeled in a manner mimicking
clinical send-outs, including source-masked research ID numbers,
sample type (serum), and a fictitious collection date to coincidewith
the date of shipment to each lab.
Selection of commercial laboratories
Four US laboratories were selected for investigation, each a rec-
ognized high-volume commercial laboratory (ie, performs the
bone marker assay at least 2 days per week and successfully par-
ticipates in a proficiency-testing program for the bone marker
assay being investigated) that offers s-CTX testing using an auto-
mated platform: ARUP Laboratories (Salt Lake City, UT, USA); Eso-
terix Laboratory Services (Calabasas Hills, CA, USA), which was
acquired by Laboratory Corporation of America (LabCorp, Bur-
lington, NC, USA); Mayo Medical Laboratories (Rochester, MN,
USA); and Quest Diagnostics (Nichols Institute, San Juan Capis-
trano, CA, USA). To prevent bias and observer variability, the lab-
oratories were unaware of the investigation; source-masked
identifiers were used for all specimens; and the specimens were
sent to labs via a third-party outpatient private clinical practice as
routine clinical specimens ordered by outpatient providers
would be sent. To control for analytical variability, specimens
were mixed, processed, and stored following established stan-
dardized procedures. The laboratories were not aware of the
study objectives and were paid in full via the standard contrac-
tual arrangements in place with the third-party clinical practice.
Timing of specimen delivery
Each laboratory was sent one archived aliquot of serum from
each pool (ie, three uniquely labeled specimens) on five dates
over a 6-month period to assess longitudinal (between-run) var-
iability of themarker measurements. Tominimize the differences
in sample thawing, samples were sent to all labs on a day of the
week chosen so that all samples would be analyzed on the same
day. Specimens were sent every six to seven weeks. For all labo-
ratories, on the fifth and final date, five uniquely labeled identical
serum specimens from each pool (for a total of 15 specimens)
were sent to each laboratory to assess within-run variability of
the marker measurement.
s-CTX assay
Each of the four labs used one of two US Food and Drug
Administration- (FDA-) approved assays run on an automated
JBMR Plus (WOA)n 2 of 6 HINDI ET AL.
platform for s-CTX measurements using an electro-chemilu-
minescence immunoassay (ECLIA). ECLIAs use two specific
monoclonal antibodies directed against the amino acid
sequence of EKAHD-β-GGR, where the aspartic acid residue
(D) is β-isomerized. To obtain a specific signal in the ECLIA, two
changes of EKAHD-β-GGR must be crosslinked.
Three of the four laboratories used the Beta-CrossLaps assay
manufactured by Roche Diagnostics (Indianapolis, IN, USA),
whereas one laboratory (Esoterix/Labcorp) used the Serum
CrossLaps assay manufactured by Immunodiagnostic Systems
Holdings PLC (IDS; Tyne and Wear, UK). Because Esoterix has
been acquired by LabCorp, any clinical specimens sent to Lab-
Corp are forwarded to Esoterix for analysis (therefore, assays sent
to either lab are run on the same assay and are thus referred to
simply as Esoterix/LabCorp).
The laboratories communicated the results by fax to the third-
party outpatient clinic, as would be done for routine clinical
specimens. These results were then forwarded to the principal
investigator for unmasked tabulation and analysis. S-CTX values
were reported by all labs in whole numbers and in picograms
per milliliter (pg/mL).
Statistical analysis
Means, SDs, and coefficients of variation (CVs, defined as
SD/mean) with 95% confidence intervals (CIs)(10) were calculated
using R Version 3.3.2 (R Foundation for Statistical Computing,
Vienna, Austria). In estimating within-lab CVs using all three
pools, as well as overall CVs, SDs were calculated with respect
to the within-pool means. We used asymptotic tests to assess
heterogeneity of the CVs between pools and labs,(11) and simula-
tion to obtain prediction intervals for the calculated reduction in
marker values for the range of observed CVs. In post hoc sensitiv-
ity analyses, we omitted results for Esoterix/LabCorp in compar-
ing longitudinal heterogeneity of the CVs across labs, and
omitted an outlying result for the postmenopausal pool
obtained by Quest in estimating longitudinal within-lab CVs.
Finally, we used a linear mixed model to assess between-lab het-
erogeneity in average measurements after accounting for vari-
ability because of pool. This analysis was implemented in Stata
Version 15.1 (StataCorp LLC, College Station, TX, USA).
Results
Reference range results
We requested that each lab provide the reference range for its s-
CTX assay. For postmenopausal women, the reported reference
ranges (all in pg/mL) were 142 to 1351 for Esoterix/Labcorp
and 104 to 1008 for ARUP andMayo. Quest did not provide post-
menopausal normative data. For premenopausal women, Esoter-
ix/Labcorp and Mayo reported reference ranges of 112 to
738 and 25 to 573, respectively, and the premenopausal refer-
ence range for ARUP and Quest was 60 to 650 for women ages
18 to 39 years and 40 to 465 for women ages 40 to 49 years.
Longitudinal reproducibility
Longitudinal reproducibility was evaluated by sending one spec-
imen from each pool to each of four labs on five separate dates
(only the first of the five identical specimens sent on the fifth
send-out was included in the longitudinal analysis). CVs for the
premenopausal pool varied from 5.0% to 14.9%, whereas those
from the mixed and postmenopausal pools varied from 3.0% to
16.0% and from 3.4% to 19.3%, respectively. There was statisti-
cally significant between-pool heterogeneity of the CVs for
Quest only (p = 0.007; Table 1).
For mixed and postmenopausal pools, there was significant het-
erogeneity of longitudinal CVs between the four labs (Table 2).
When results from Esoterix/LabCorp, which used a different assay,
was removed from the calculation, the heterogeneity of CVs
between labswas no longer statistically significant for the premeno-
pausal (p = 0.52) or mixed (p = 0.73) pools, but remained significant
for the postmenopausal pool (p < 0.001) (Table 2, third column).
Combining the premenopausal, mixed, and postmenopausal
pool results for each laboratory (Fig. 1), the overall longitudinal
within-lab CVs for s-CTX were recalculated (Table 3) and ranged
from 3.5% (ARUP) to 13.9% (Esoterix/Labcorp). The p value for
overall heterogeneity of the CVs across labs was <0.001, both
before and after excluding Esoterix/LabCorp. In addition, the
p value for overall heterogeneity of the combined means for all
three pools across labs, which ranged from 436 (Quest) to
579 (Esoterix/LabCorp) was <0.001 (Table 3).
Table 1. Longitudinal Within-Lab Reproducibility of s-CTX at Four US Commercial Labsa
Lab Pool Assay N Mean  SD (pg/mL) CV, % (95% CI)
Heterogeneity of
CV between poolsb
ARUP PRE ECLIA, Roche 5 394  19.8 5.0 (3.0 to 14.6) p = 0.47
ARUP MIX ECLIA, Roche 5 449  13.7 3.0 (1.8 to 8.8)
ARUP POST ECLIA, Roche 5 496  16.9 3.4 (2.0 to 9.8)
Esoterix/LabCorp PRE ECLIA, IDS 5 518  77.0 14.9 (8.9 to 44.8) p = 0.94
Esoterix/LabCorp MIX ECLIA, IDS 5 573  91.4 16.0 (9.5 to 44.8)
Esoterix/LabCorp POST ECLIA, IDS 5 645  87.2 13.5 (8.1 to 40.4)
Mayo PRE ECLIA, Roche 5 430  29.8 6.9 (4.1 to 20.1) p = 0.38
Mayo MIX ECLIA, Roche 5 486  18.5 3.8 (2.3 to 11.0)
Mayo POST ECLIA, Roche 5 540  25.7 4.8 (2.9 to 13.7)
Quest PRE ECLIA, Roche 5 408  35.0 8.6 (5.1 to 25.0) p < 0.001
Quest MIX ECLIA, Roche 5 448  19.6 4.4 (2.6 to 12.6)
Quest POST ECLIA, Roche 5 451  86.3 19.3 (11.5 to 60.5)c
s-CTX = Serum collagen type-I crosslinked C-peptide; CV = coefficient of variation; PRE = premenopausal pool; POST = postmenopausal pool;
MIX = equal proportion of the pre- and postmenopausal pools; ECLIA = electro-chemiluminescence immunoassay.
aCalculated from five identical serum specimens sent to each lab five times over a 6-month period.
bLab-specific p value for heterogeneity of CVs for premenopausal, mixed, and postmenopausal pools.
cWhen a single outlier is removed from the postmenopausal pool, Quest mean  SD is 500  24.2 and CV (95% CI) is 4.8 (2.7 to 18.2).
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Within-run reproducibility
Cross-sectional within-run reproducibility for each lab was evalu-
ated by sending five identical specimens, each with unique
patient identifiers, from each of three pools on one date (chosen
as the fifth and final send-out date). For the premenopausal pool
(Table 4), cross-sectional within-run CVs varied from 1.1% (Mayo)
to 10.4% (Esoterix/LabCorp). For the mixed pool, CVs varied from
1.3% (ARUP) to 9.3% (Esoterix/LabCorp). For the postmenopausal
pool, CVs varied from 2.8% (ARUP) to 8.0% (Esoterix/LabCorp).
There was statistically significant heterogeneity of CVs among
pools at Mayo only (Table 4), which appeared to have a higher
CV (6.8%) for the mixed pool compared with the pre- and post-
menopausal pools (p = 0.002).
There was also statistically significant heterogeneity of cross-
sectional within-run CVs among labs within each pool (p < 0.05;
Table 5). After Esoterix/LabCorp was removed from the calcula-
tion, significant variability within the premenopausal (p < 0.001)
and mixed (p = 0.017) pools remained.
Combining results from all three pools sent to each lab on the
fifth and final shipment, cross-sectional within-run CVs for s-CTX
were calculated (Table 6). CVs varied from 2.1% (ARUP) to 8.6%
(Esoterix/LabCorp). The p value for heterogeneity across labs
was <0.001 both before and after excluding Esoterix/LabCorp.
Simulation of monitoring with s-CTX during treatment
In the setting of treatment monitoring with s-CTX, the following
hypothetical example provides some insight into the clinical
implications of our study. If s-CTX measurements were obtained
(using the same lab) prior to and 3 months after starting bispho-
sphonate treatment, we used the observed laboratory reproduc-
ibility in this study to simulate 95% prediction intervals for the
observed percent reduction in s-CTX when the true value falls
by 50%. In other words, this analysis provides the plausible
ranges of reported results for a true 50% reduction in s-CTX. In
this hypothetical example, the prediction interval for the percent
reduction in s-CTX estimated by a lab with a longitudinal CV of
3.5% (ARUP) is an estimated 45% to 55%. In contrast, for a labo-
ratory with a longitudinal CV of 13.9% (such as Esoterix/LabCorp),
the plausible range would be 35% to 71%.
Discussion
In this masked study of identical specimens, both the longitudi-
nal and cross-sectional reproducibility of s-CTX was highly vari-
able at high-volume US commercial labs. For each lab,
variability was generally similar for premenopausal, postmeno-
pausal, and mixed pools, but was significantly greater for the
one laboratory utilizing the IDS assay (ie, Esoterix/LabCorp). Con-
versely, s-CTX reproducibility was better among the three labs
utilizing the Roche assay, but statistically significant differences
between laboratories were documented for specific pools even
among those using the same s-CTX assay. We cannot determine
if this variability is attributable to the assay used or to the labora-
tory performing the assay. However, our results confirm that in
clinical practice, serial measurements utilizing the same assay
and laboratory will result in more stable results over time.
A limitation of the present study is the small number of labs
evaluated. However, the labs evaluated represent high-volume,
well-recognized commercial labs collectively responsible for a
Table 2. Longitudinal Between-Lab Reproducibility of s-CTX
Within Each Pool
Pool
p value for heterogeneity
of CVs (all 4 labs)a
p value for heterogeneity
of CVs (after removal
of Esoterix/LabCorp)a
PRE 0.08 0.52
MIX <0.001 0.73
POST 0.001 <0.001
s-CTX = Serum collagen type-I crosslinked C-peptide; CV = coefficient of
variation; PRE = premenopausal pool; POST = postmenopausal pool; MIX
= equal proportion of the pre- and postmenopausal pools.
ap value for heterogeneity of longitudinal CVs between labs.
Fig. 1. Six-month longitudinal reproducibility of serum collagen type-I
crosslinked C-peptide (s-CTX) at four US commercial labs (all pools
combined).
Table 3. Longitudinal Within-Lab Reproducibility of s-CTX (All Pools Combined)
Lab N Mean  SD
Heterogeneity
of means
between
all 4 labs
Heterogeneity
of means after
removal of Esoterix/
Lab Corp CV, % (95% CI)
Heterogeneity
of CV between
all 4 labs
Heterogeneity
of CV between
labs after removal
of Esoterix/
Lab Corp
ARUP 15 446  15.8 p < 0.001 p < .001 3.5 (2.6 to 5.6) p < 0.001 p < 0.001
Esoterix/LabCorp 15 579  80.5 13.9 (10.1 to 22.2)
Mayo 15 485  23.9 4.9 (3.6 to 7.8)
Quest 15 436  53.7 12.3 (9.0 to 19.6)
s-CTX = Serum collagen type-I crosslinked C-peptide; CV = coefficient of variation.
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significant proportion of s-CTX assays conducted in the United
States. Another limitation is that longitudinal reproducibility was
tested over a period of 6 months, and not a longer period asmight
be anticipated in clinical practice. A third limitation of the present
study is that although two BTMs are recommended by the IOF-
IFCC,(2) we only assessed s-CTX, recognizing that there are currently
no automated assays for s-PINP that are FDA-approved. However,
specimens have been archived for analysis at a later date once
automated assays for s-PINP receive FDA-approval. Therefore, the
laboratory reproducibility of s-PINP remains an area to be studied.
Finally, our study lacks a sample with a markedly elevated bone
turnover level, as the pool created to reflect high turnover turned
out to be relatively close in value to the pool with low turnover.
A strength of this study is the testing of multiple pooled sam-
ples for s-CTX representing normal to elevated marker values to
approximate populations encountered in routine clinical prac-
tice. Furthermore, the pooling of specimens minimized interfer-
ing effects of medications or other factors specific to a single
volunteer. Although pooled samples do not behave exactly like
individual patient samples, the aim of our study was to examine
heterogeneity attributed to the laboratory and not to the individ-
ual patient. Pooling in this setting is therefore a useful mecha-
nism to eliminate the confounding factor of individual patient
heterogeneity.
Another strength of our study is that the commercial laborato-
ries were blinded to the investigation. The laboratories were not
aware of the study objectives and were paid in full via the stan-
dard contractual arrangements in place with the third-party clin-
ical practice. Thus, our protocol differs from announced and
unblinded proficiency testing conducted according to the Clini-
cal Laboratory Improvement Amendments and the College of
American Pathologists, where reproducibility may be at its best.
The purpose of blinding the commercial laboratories to the
investigation in this, as well as our previous study,(9) was to pre-
vent bias and observer variability. Moreover, we wanted to
ensure that the samples were processed exactly the same as rou-
tine clinical samples. Finally, it should be noted that CTX is more
stable in EDTA plasma than in serum. For this reason, the
National Bone Health Alliance (NBHA) prefers CTX in EDTA
plasma if a lab is not able to process a sample immediately.(12)
However, we used serum CTX in our study to best reflect clinical
Table 4. Cross-Sectional Within-Run Reproducibility of s-CTX at Four US Commercial Labsa
Lab Group Assay N Mean  SD (pg/mL) CV, % (95% CI)
Heterogeneity of
CV between poolsb
ARUP PRE ECLIA, Roche 5 412  7.0 1.7 (1.0 to 4.9) p = 0.21
ARUP MIX ECLIA, Roche 5 459  5.9 1.3 (0.8 to 3.7)
ARUP POST ECLIA, Roche 5 515  14.3 2.8 (1.7 to 8.0)
Esoterix/LabCorp PRE ECLIA, IDS 5 411  42.9 10.4 (6.2 to 30.7) p = 0.84
Esoterix/LabCorp MIX ECLIA, IDS 5 514  48.0 9.3 (5.6 to 27.3)
Esoterix/LabCorp POST ECLIA, IDS 5 574  46.0 8.0 (4.8 to 23.3)
Mayo PRE ECLIA, Roche 5 450  5.1 1.1 (0.7 to 3.3) p = 0.002
Mayo MIX ECLIA, Roche 5 479  32.8 6.8 (4.1 to 19.9)
Mayo POST ECLIA, Roche 5 543  17.1 3.1 (1.9 to 9.1)
Quest PRE ECLIA, Roche 5 373  24.6 6.6 (3.9 to 19.1) p = 0.51
Quest MIX ECLIA, Roche 5 421  21.9 5.2 (3.1 to 15.0)
Quest POST ECLIA, Roche 5 487  18.8 3.9 (2.3 to 11.1)
s-CTX = Serum collagen type-I crosslinked C-peptide; CV = coefficient of variation; PRE = premenopausal pool; POST = postmenopausal pool; MIX =
equal proportion of the pre- and postmenopausal pools; ECLIA = electro-chemiluminescence immunoassay.
aCalculated from five identical serum specimens set to each lab on one day.
bLab-specific p value for heterogeneity of CVs for premenopausal, mixed, and postmenopausal pools.
Table 5. Cross-Sectional Within-Run Reproducibility of s-CTX
Within Each Pool
Pool
p-value for
heterogeneity
of CVs (all four labs)a
p-value for heterogeneity
of CVs (after removal
of Esoterix/LabCorp)a
PRE <0.001 <0.001
MIX 0.014 0.017
POST 0.031 0.75
s-CTX = Serum collagen type-I crosslinked C-peptide; CV = coefficient of
variation; PRE = premenopausal pool; POST = postmenopausal pool; MIX
= equal proportion of the pre- and postmenopausal pools.
ap-value for heterogeneity across labs for cross-sectional within run CVs.
Table 6. Cross-Sectional Within-Lab Reproducibility for s-CTX (All Pools Combined)
Lab N Mean  SD CV, % (95% CI)
Heterogeneity
of CV between
all 4 labsa
Heterogeneity
of CV between labs after
removal of Esoterix/Labcorpa
ARUP 15 462  9.5 2.1 (1.5 to 3.3) p < 0.001 p < 0.001
Esoterix/LabCorp 15 500  42.8 8.6 (6.3 to 13.6)
Mayo 15 491  20.9 4.3 (3.1 to 6.7)
Quest 15 427  26.6 6.2 (4.6 to 9.8)
s-CTX = Serum collagen type-I crosslinked C-peptide; CV = coefficient of variation.
ap value for heterogeneity across labs for cross-sectional within run CVs.
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practice in the United States because the majority of US com-
mercial labs use serum for CTX processing. Moreover, in line with
NBHA recommendations to reduce preanalytical variability, we
took careful measures to ensure standardized sample handling
and patient preparation.
BTMs are valuable tools for assessing the dynamic nature of
bone. They may enhance the estimation of fracture risk when
pairedwith static BMDdata, andmay independently provide valu-
able information about treatment response and efficacy when
monitoring therapy in osteoporosis management.(1,3–5) Despite
the clinical potential of BTMs, current assays for BTMs lack com-
monly accepted standardizations, limiting the application of BTMs
to routine clinical practice.(6–9) A number of organizations, includ-
ing the IOF and IFCC, have recognized the need to advance the
field of BTMs and address the limitations of their use for routine
clinical practice.(2,7) Poor reproducibility is a major barrier to the
use of biochemical markers of bone turnover in clinical practice.
This challenge in clinical practice is further complicated by the fact
that information about the particular assay and platform used by a
given labmay not be disclosed. For example, in this study only the
results from ARUP and Mayo included the assay employed. Fur-
ther, the results of laboratory proficiency testing are not widely
available to practicing clinicians.
In conclusion, in this blinded analysis using identical aliquots
of pooled serum, we found that the longitudinal and within-
run reproducibility of s-CTX measurements differed across four
US commercial laboratories, even after accounting for different
assays. Based on these differences, we estimate that some labs
may have suboptimal reproducibility, which reduces the utility
of serial s-CTX measurements. Therefore, in clinical practice, the
importance of utilizing the same highly reproducible laboratory
over time should be emphasized to optimize the utility of serial
s-CTX measurements obtained for the purpose of monitoring
therapy. Before the routine use of s-CTX can be recommended,
additional studies are needed to determine the causes of labora-
tory variability.
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